BioCentury | Apr 3, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...Musculoskeletal disease Calcium release-activated calcium channel (CRAC); stromal interaction molecule 1 (STIM1); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1...
...p.R304M mutation in STIM1 in two patients with Stormorken syndrome and the p.P2452 mutation in ORAI1...
...cells, expression of the STIM1 mutation caused constitutive activation of CRAC and expression of the ORAI1...
BioCentury | Aug 8, 2013
Targets & Mechanisms

CRACking pancreatitis

...see "CRACkdown on pancreatitis"). The complex consists of transmembrane protein 142A ( ORAI1 ; TMEM142A ; CRACM1...
...of digestive problems in children with genetically defective CRACM1 protein may suggest that at least CRACM1...
...to acute pancreatitis.CRACs consist of channel subunits such as transmembrane protein 142A ( ORAI1 ; TMEM142A ; CRACM1...
BioCentury | Aug 1, 2013
Distillery Therapeutics

Indication: Cancer

...SK3); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1) Mouse studies suggest inhibiting the interaction between the SK3 and ORAI1...
...and in mouse xenograft models, the lipid ohmline, which inhibits the localization of SK3 and ORAI1...
...cell migration and bone metastasis compared with vehicle. Next steps include determining whether expression of SK3-ORAI1...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Cancer

...Transmembrane protein 142A (ORAI1; TMEM142A; CRACM1); Stromal interaction molecule-1 (STIM1) In vitro and mouse studies suggest that ORAI1...
...In vitro, inhibition of Ca2+ entry with SKF96365 or small interfering RNA knockdown of either ORAI1...
BioCentury | Jan 5, 2009
Company News

Synta, Roche deal

The companies partnered to discover, develop and commercialize compounds targeting calcium release-activated calcium modulator (CRACM) channels to treat inflammatory diseases. Synta will receive research funding for two years, and Roche will receive worldwide rights to...
BioCentury | Jan 5, 2009
Finance

Ebb & Flow

Next to having cash in the bank, the next best thing is having a bankroll waiting on the shelf. In the closing days of 2008, Array BioPharma , Ista and MediGene each made moves that promise...
BioCentury | Dec 31, 2008
Company News

Synta, Roche in inflammation deal

Synta (NASDAQ:SNTA) and Roche (SWX:ROG) partnered to discover, develop and commercialize compounds targeting calcium release-activated calcium modulator (CRACM) channels to treat inflammatory diseases. Synta will receive $25 million up front and will be eligible for...
BioCentury | Dec 10, 2007
Emerging Company Profile

CalciMedica: CRACking toxicity

...activation, developing inhibitors of the complex formed by stromal interaction molecule-1 ( STIM1 ) and ORAI1...
...TPTX, La Jolla, Calif.), has rights to TPTX's patent applications covering uses of STIM1 and ORAI1...
...calcium release-activated calcium ( CRAC ) channel activity. Recent studies have shown that transmembrane protein 142A (ORAI1, TMEM142A...
BioCentury | May 14, 2007
Company News

CalciMedica, TorreyPines, CBR Institute for Biomedical Research deal

...fees, milestones and royalties. Separately, CalciMedica received exclusive rights to develop therapeutics against the institute's Orai1...
Items per page:
1 - 9 of 9